FFR is the gold standard (Dr. William Fearon) Dr. William reported on the benefits of using FFR: • A high degree of accuracy in identifying lesions that cause ischemia. • It allows you to specify angioplasty safely. • It improves results when compared to standard practice. • It is technically safe, easy to perform, economical…
THRIVE: Niacin/laropiprant extended release showed no significant cardiovascular benefit.
The THRIVE study, (also known as HPS2-THRIVE), was a multicenter clinical trial designed to test the hypothesis that the increase in HDL, (using ER niacin/laropiprant), could prevent vascular events in a high risk population already receiving statin standard therapy. Between April 2007 and July 2010 a total of 25,673 randomized patients in China, the UK…
PREVAIL: LAA occlusion versus anticoagulation with warfarin to prevent stroke in patients with non-valvular atrial fibrillation.
An hour before the presentation of the PREVAIL study, the ACC announced the cancellation of the release of the study results. Due to an error in the email system, results of the study were reported a few hours before his presentation. The ACC in an unprecedented decision cancelled the presentation of the study as well…
TCT Session
Alan Wilson and Szeto Zajarias show that vascular complications of the trans-femoral path remain an important factor because of the high profile of the catheters used in TAVI and the appearance of smaller devices, as well as the experience of surgeons, will progressively reduce complication rates. Josep Rodes-Cabau commented about the negative impact a stroke…